A milestone has been celebrated by a biopharmaceutical company.
Slough-based UCB marked 10 years since they acquired British biotechnology company, Celltech, in an event earlier this month.
At the time of the take-over, Celltech was Europe’s leading biotechnology company.
The company, whose UK head office is in Bath Road, also celebrated the investment in research and development (R&D) and world class drug discovery and development that has happened since 2004.
“By bringing together Celltech and UCB we have pushed the boundaries of science to discover breakthrough medicines that can improve the lives of millions of people across the globe,” said Dr Roch Doliveux, UCB’s chief executive officer.
UCB specialised in small-molecule pharmaceutical chemistry and when it combined with Celltech’s advanced antibody technologies, they transformed into a leading European biopharmaceutical company.
Since the takeover, the company has significantly increased its annual UK R&D expenditure from £84m a year in 2003, to £142m in 2012, making it one of the UK’s leading biopharmaceutical R&D investors.
It employs more than 700 staff in the UK, of which more than 400 work in R&D.